当前位置:首页 - 行情中心 - 东亚药业(605177) - 财务分析 - 利润表

东亚药业

(605177)

  

流通市值:21.65亿  总市值:22.06亿
流通股本:1.13亿   总股本:1.15亿

利润表

报告期2025-06-302025-03-312024-12-312024-09-30
公司类型通用通用通用通用
一、营业总收入415,858,305.39190,921,213.831,198,238,535.39963,019,242.47
  营业收入415,858,305.39190,921,213.831,198,238,535.39963,019,242.47
二、营业总成本425,107,404.13193,939,111.071,173,707,357.93914,079,555.24
  营业成本290,462,901.6123,394,635.74865,663,163.87703,230,309.84
  税金及附加5,138,105.932,437,450.1511,362,718.638,539,592.24
  销售费用7,077,804.561,759,543.4915,387,268.4710,982,915.66
  管理费用78,081,656.8843,208,414.35170,269,093.67127,438,407.37
  研发费用42,365,947.1223,009,005.87117,016,684.5667,140,483.98
  财务费用1,980,988.04130,061.47-5,991,571.27-3,252,153.85
  其中:利息费用5,095,918.511,936,606.192,039,662.82,478,028.51
  其中:利息收入2,516,608.41,306,491.435,674,745.084,289,818.64
三、其他经营收益
  加:投资收益1,467,591.82737,521.133,943,815.783,342,771.63
  资产处置收益-4,303.49-5,963.93-3,130,864-90,624.45
  资产减值损失(新)-31,980,426.01-12,629,703.08-144,052,482.6-3,552,573.56
  信用减值损失(新)-43,149.173,330,066.74-1,179,208.39-3,315,686.94
  其他收益7,288,309.13,955,914.0418,154,530.3514,544,601.08
四、营业利润-32,521,076.49-7,630,062.34-101,733,031.459,868,174.99
  加:营业外收入187,455.2976,004.56526,138.6130,148
  减:营业外支出1,811,629.0684,964.9516,965,194.784,445,608.27
五、利润总额-34,145,250.26-7,639,022.73-118,172,087.5755,452,714.72
  减:所得税费用-3,880,698.64-694,118.56-17,472,628.0710,296,716.32
六、净利润-30,264,551.62-6,944,904.17-100,699,459.545,155,998.4
(一)按经营持续性分类
  持续经营净利润-30,264,551.62-6,944,904.17-100,699,459.545,155,998.4
(二)按所有权归属分类
  归属于母公司股东的净利润-30,228,272.8-6,919,576.54-100,660,051.8445,169,152.65
  少数股东损益-36,278.82-25,327.63-39,407.66-13,154.25
  扣除非经常损益后的净利润-35,880,868.77-10,505,893.27-98,408,150.0138,084,911.87
七、每股收益
  (一)基本每股收益-0.26-0.06-0.90.4
  (二)稀释每股收益-0.2-0.05-0.690.31
九、综合收益总额-30,264,551.62-6,944,904.17-100,699,459.545,155,998.4
  归属于母公司股东的综合收益总额-30,228,272.8-6,919,576.54-100,660,051.8445,169,152.65
  归属于少数股东的综合收益总额-36,278.82-25,327.63-39,407.66-13,154.25
公告日期2025-08-292025-04-302025-04-302024-10-31
审计意见(境内)标准无保留意见
TOP↑